<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20191023045206N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-05-06</date_registration>
      <primary_sponsor>Ahvaz University of Medical Sciences</primary_sponsor>
      <public_title>Dexmedetomidine versus remifentanil in post operative pain control after spine surgery</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the effect of Dexmedetomidine and Remifentanil on post operative pain control after spine surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-12-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/44144</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Diagnostic, Randomization description: In this study spinal surgery patients will be devided to two groups recieving dexmedetomidine and remifentanile in random using random digits table, Blinding description: The anesthesiologist who has responsible for the patients management of anesthesia will administer the medicine (s) via coded syringes had been prepared previously and will not aware of the injected drug (dexmedetomidin or remifentanile), and anesthesia nurse who is responsible for collection of patients information and study variables is unaware of the administered drug will record the check- list during surgery and in the recovery. Also the patient is unaware of the injected medicine.</study_design>
      <phase>3</phase>
      <hc_freetext>Post operative pain.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group1:serum ringer lactate 5 ml/kg,midazolam 0.02 mg/kg,fentanyl 2mcg/kg,propofol1.5 mg/kg,atracuriom 0.5 mg/kg,morphine sulfate 0.1 mg/kg for induction and dexmedetomidine0.1mcg/kg in 10 minutes(Abureyhan _Iran co.) and for maintnance propofol 100 to 150 mcg/kg besides dexmedetomidine0.1mcg/kg/h will recieve. Intervention 2: Intervention group2:serum ringer lactate 5 ml/kg,midazolam 0.02 mg/kg,fentanyl 2mcg/kg,propofol1.5 mg/kg,atracuriom 0.5 mg/kg,morphine sulfate 0.1 mg/kg for induction and remifentanile bollus dose(Abureyhan _Iran co.) 1 mcg/kg and for maintnance propofol 100 to 150 mcg/kg besides 1 mcg/kg/min remifentanile will recieve.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
data after the end of study will be avalable.

When:
from 2021

To whom:
physicians

Conditions:
using for future studies.

Where to obtain:
send E-Mail to Mohammad.zafari2@yahoo.com

How to obtain:
filling the study reguest form

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Farahzad Janatmakan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golestan avenue</address>
        <city>Ahwaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6136766337</zip>
        <telephone>+98 61 3374 8388</telephone>
        <email>janatmakan-f@ajums.ac.ir</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nozar Nassajian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golestan avenue</address>
        <city>Ahwaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6136768831</zip>
        <telephone>+98 61 3376 6841</telephone>
        <email>nasajian-n@ajums.ac.ir</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Elective surgery of spine
age of 18-65 years
ASA class 1,2</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Previous spine surgery
Opium addiction
Alcohol addiction
Neurological disease
Neuromuscular disease
Psychological disease
Pulmonary disease
Cardiovascular disease
Analgesic consumer(cox-2 inhibitors)
Operative unpredictable events (massive bleeding)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R52.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Pain, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Diagnosis</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group1:serum ringer lactate 5 ml/kg,midazolam 0.02 mg/kg,fentanyl 2mcg/kg,propofol1.5 mg/kg,atracuriom 0.5 mg/kg,morphine sulfate 0.1 mg/kg for induction and dexmedetomidine0.1mcg/kg in 10 minutes(Abureyhan _Iran co.) and for maintnance propofol 100 to 150 mcg/kg besides dexmedetomidine0.1mcg/kg/h will recieve.</i_keyword>
      <i_keyword>Intervention group2:serum ringer lactate 5 ml/kg,midazolam 0.02 mg/kg,fentanyl 2mcg/kg,propofol1.5 mg/kg,atracuriom 0.5 mg/kg,morphine sulfate 0.1 mg/kg for induction and remifentanile bollus dose(Abureyhan _Iran co.) 1 mcg/kg and for maintnance propofol 100 to 150 mcg/kg besides 1 mcg/kg/min remifentanile will recieve.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: 30, 60 and 120 minutes and 24 hours after surgery. Method of measurement: Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Systolic blood pressure variance. Timepoint: 30, 60 and 120 minutes and 24 hours after surgery. Method of measurement: blood pressue  monitor.</sec_outcome>
      <sec_outcome>Diastolic blood pressue variance. Timepoint: 30, 60 and 120 minutes and 24 hours after surgery. Method of measurement: blood pressure monitoring.</sec_outcome>
      <sec_outcome>Heart rate variance. Timepoint: 30, 60 and 120 minutes and 24 hours after surgery. Method of measurement: heart rate monitoring.</sec_outcome>
      <sec_outcome>O2 saturation variance. Timepoint: 30, 60 and 120 minutes and 24 hours after surgery. Method of measurement: Pulseoxymetry.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ahvaz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-11-16</approval_date>
        <contact_name>Ethics committee of Ahwaz University of Medical Sciences</contact_name>
        <contact_address>Golestan hospital; Golestan avenue Ahwaz Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
